Uncategorized
Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug
Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement
Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial
Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation
GSK Launches Groundbreaking Study on Shingrix and Dementia Risk Reduction
GSK, Shingrix, dementia, UK Dementia Research Institute, Health Data Research UK, NHS data, real-world experiment
Biogen’s New Global Headquarters: Consolidating Operations in Cambridge
Biogen, Cambridge, Kendall Square, headquarters consolidation, innovation hub, 2028 opening
Surrozen sets its sights on ophthalmology after binning liver programme
Ophthalmology specialty, Severe (severity modifier)
Future in doubt as Opthea’s AMD drug flunks first pivotal study
Opthea ‘s, Opthea, Future, Clinical Research
23andMe files for bankruptcy as CEO Anne Wojcicki steps down to become bidder
Bankruptcy, CEO, Anne, Customer
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited
Unitys eye treatment fails to match Eylea, though analysts still see a path forward
analysts, Eylea, match Eylea, Macular edema due to diabetes mellitus